These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29395100)

  • 1. The challenge of peripheral arterial disease: How do we improve outcome?
    Stock JK
    Atherosclerosis; 2018 Mar; 270():196-198. PubMed ID: 29395100
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 inhibition in PAD patients - a rising star in secondary prevention?
    Vasa; 2018 Feb; 47(2):157. PubMed ID: 29460708
    [No Abstract]   [Full Text] [Related]  

  • 5. Poststatin Lipid Therapeutics: A Review.
    Jia X; Lorenz P; Ballantyne CM
    Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of statins in patients with peripheral artery disease.
    Corrado E; Mignano A; Coppola G
    Trends Cardiovasc Med; 2020 Jul; 30(5):257-262. PubMed ID: 31307839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
    Cho L; Dent R; Stroes ESG; Stein EA; Sullivan D; Ruzza A; Flower A; Somaratne R; Rosenson RS
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):365-372. PubMed ID: 30073585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 11. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease.
    Lee JH; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    J Vasc Surg; 2016 Mar; 63(3):756-63. PubMed ID: 26603545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
    Banach M; Penson PE
    Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511
    [No Abstract]   [Full Text] [Related]  

  • 13. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease.
    Foley TR; Singh GD; Kokkinidis DG; Choy HK; Pham T; Amsterdam EA; Rutledge JC; Waldo SW; Armstrong EJ; Laird JR
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28711864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
    Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K
    J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease.
    Dittrich J; Beutner F; Teren A; Thiery J; Burkhardt R; Scholz M; Ceglarek U
    Atherosclerosis; 2019 Feb; 281():17-24. PubMed ID: 30594773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid Optimization in Lower Extremity Peripheral Arterial Disease.
    Sucharitkul PPJ; Jones KL; Scott DJA; Bailey MA
    Ann Vasc Surg; 2021 Oct; 76():542-554. PubMed ID: 33951531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies.
    Gragnano F; Calabrò P
    Atherosclerosis; 2018 Feb; 269():219-228. PubMed ID: 29407597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany.
    Waßmuth S; Rohe K; Noack F; Noutsias M; Treede H; Schlitt A
    Vasc Health Risk Manag; 2019; 15():477-483. PubMed ID: 31802881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.
    Robinson JG; Heistad DD; Fox KA
    Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD.
    Mahtta D; Ahmed ST; Ramsey DJ; Akeroyd JM; Lee MT; Rodriguez F; Michos ED; Itchhaporia D; Nasir K; Alam M; Jneid H; Ballantyne CM; Petersen LA; Virani SS
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):745-754. PubMed ID: 32840709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.